|
Press Releases |
|
 |
|
Tuesday, June 7, 2022 |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
祝賀!國際頂級醫學期刊《自然-醫學》同時發表兩篇關於華領醫藥全球首創糖尿病新藥多格列艾汀的III期研究結果的同行評議論文 |
華領醫藥(“公司”,香港聯交所主機板股份代號:2552.HK)今日宣佈,國際頂級醫學刊物《自然-醫學》(Nature Medicine)雜誌同時線上發表了兩篇公司全球首創糖尿病新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的III期註冊臨床研究結果的同行評議論文。 more info >> |
|
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文 |
华领医药(“公司”,香港联交所主板股份代号:2552.HK)今日宣布,国际顶级医学刊物《自然-医学》(Nature Medicine)杂志同时在线发表了两篇公司全球首创糖尿病新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的III期注册临床研究结果的同行评议论文。 more info >> |
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
Thursday, March 17, 2022 |
|
华领医药公布2021年全年业绩 |
华领医药(「公司」,香港联交所股份代号:2552),今天宣布公司及其附属公司截至2021年12月31日止,经审核的全年业绩(「报告期」)。 more info >> |
|
華領醫藥公佈2021年全年業績 |
華領醫藥(「公司」,香港聯交所股份代號:2552),今天宣佈公司及其附屬公司截至2021年12月31日止,經審核的全年業績(「報告期」)。 more info >> |
|
Hua Medicine Announces 2021 Annual Results |
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
Sunday, September 26, 2021 |
|
研究者公布有关多格列艾汀糖尿病缓解的重要研究 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在苏州举办的第六届中国医药创新与投资大会(The China BioMed Innovation and Investment Conference,以下简称CBIIC)上,中华医学会糖尿病学分会常委、南京市第一医院内分泌科主任马建华教授作为主要研究者之一,公布了一项名为DREAM的临床研究结果,研究显示华领医药全球首创新药葡萄糖激酶激活剂多格列艾汀(dorzagliatin) 有望在糖尿病缓解方面取得进展。 more info >> |
|
研究者公佈有關多格列艾汀糖尿病緩解的重要研究 |
more info >> |
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Singapore's Digital Finance Model in Focus at the BFSI IT Summit - Singapore 2025
Aug 11, 2025 18:26 HKT/SGT
|
|
|
WRC 2025: Shoucheng Showcases Full Robotics Value Chain
Aug 11, 2025 16:27 HKT/SGT
|
|
|
Intellifusion Submits an Application to List on the Hong Kong Stock Exchange: A National Breakthrough in AI Inference Chips
Aug 11, 2025 16:25 HKT/SGT
|
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 11, 2025 16:25 HKT/SGT
|
|
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 16:03: JST
|
|
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 15:03 HKT/SGT
|
|
|
31 Concept to Debut Patent-Pending Technology at ISS Asia 2025 in Singapore
Aug 11, 2025 13:13 HKT/SGT
|
|
|
31 Concept將在2025年新加坡ISS Asia首度發佈其申請專利的新技術
Aug 11, 2025 13:13 HKT/SGT
|
|
|
Qube Celebrates 20 Years of Business Events Impact with Industry Recognition and Vision for the Future
Aug 11, 2025 12:03 HKT/SGT
|
|
|
TransNusa Focuses on Organic Growth to Strengthen Network Connectivity in China
Aug 11, 2025 11:00 HKT/SGT
|
|
|
沙烏地電力公司2025年第二季淨利成長22%
Aug 11, 2025 11:00 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
康沣生物中期业绩创纪录 呼吸介入产品驱动收入激增162%
Aug 11, 2025 10:41 HKT/SGT
|
|
|
Shoucheng-Backed Data Center REITs Surge on Market Debut
Aug 11, 2025 09:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|